Alzheimer’s disease (AD) is a type of neurodegenerative disorder which is responsible for
many cognitive dysfunctions. According to the most accepted cholinergic hypothesis, cholinesterases
have a major role in AD symptoms. The use of small molecules as inhibitors is one of the most useful strategies to control
AD. In the present work, a series of N-phenylthiazol-2-amine derivatives was screened against acetylcholinesterase
(AChE) from Electrophorus electricus and butyrylcholinesterase (BChE) from horse serum by using Ellman’s method,
using neostigmine and donepezil as reference drugs. Some of the assayed compounds proved to be potent inhibitors for
AChE and BChE activity. N-(2,3-dimethylphenyl)thiazol-2-amine, 3j was found to be the most active inhibitor among the
series with IC50 value of 0.009 ± 0.002 µM and 0.646 ± 0.012 µM against AChE and BChE, respectively. Molecular
docking studies were carried out in order to better understand the ligand binding site interactions.
Keywords: N-Phenylthiazol-2-amine, Alzheimer's disease, acetylcholinesterase, butyrylcholinesterase.
Rights & PermissionsPrintExport